Call for Participants: Type II Diabetes Research Subjects Needed
Posted on: Tuesday, 7 March 2006, 09:00 CST
Northern Illinois research fellow Theresa M. Schultz, R.D., L.D.N., announced today a call for research subjects in her current type II diabetes study. In the study, Ms. Schultz will examine the effects of R-alpha lipoic acid on HbA1c, lipid levels, and blood pressure in type 2 diabetics.
R-alpha lipoic acid, used in conjunction with biotin, is believed to have an active role in balancing insulin production with glucose uptake. Imbalances, often severe, are a result of adult-onset or type II diabetes.
"Lipoic supplements have been studied and prescribed in Europe for over 20 years, but little has been done in the United States," said Ms. Schultz. "In our study we hope to recruit people actively suffering from type II diabetes and monitor their A1C, cholesterol, and blood pressure, to a carefully balancing supplement."
Glucorell, Inc., a Florida-based natural supplement manufacturer, will provide the same material used for use in the trial that is used in Insulow. Created specifically for diabetics and those at risk of diabetes, Insulow addresses the root cause of diabetes - insulin resistance, helping to increase insulin production and improve glucose uptake according to company officials. Similar to the familiar marriage of vitamin D and calcium, the two active ingredients in Insulow, R-lipoic acid and biotin, work in harmony to ensure a proper balance between insulin production and glucose uptake. Insulow has no known adverse side effects and can even reduce fat gain associated with a variety of diabetes medications. "Not all lipoic acid supplements are the same," said Larry Berube, president of Glucorell. "Insulow's formula is based on more than two decades of research and more than a dozen clinical studies in Europe."
In these European trials, many patients experienced significant improvements in balancing blood sugar levels, often to the point of eliminating the need for other diabetes medications.
Subject Criteria
Volunteers for the study must be type II diabetics age 21 to 65 years of age, non-smokers in otherwise good health. They must be willing to participate in a double-blind test of dietary supplement medication or placebo. Participants will not be required to nor are they encouraged to abandon their current diabetic medication and dietary regime. For further information on participation, volunteers should call 630-365-2814 or email Tschultz@niu.edu.
About Glucorell Inc.
Glucorell Inc. was founded in 2001 to introduce scientifically proven, all natural supplements not yet available in the U.S. Its first product, Insulow, was created specifically for diabetics and those at risk of diabetes, to manage blood glucose levels naturally. Insulow is available nationwide at Longs Drugs, Osco Drug, Savon Drugs, and Shaw's. Insulow may also be purchased online through http://www.cvs.com, http://www.amazon.com, and http://www.drugstore.com. For more information, go to http://www.insulow.com or call 1-866-INSULOW.
"Insulow" and "Glucorell-R" are registered trademarks of Glucorell Inc.
Source: Business Wire
Related Articles
- New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions
- American Diabetes Wholesale Donates Free Diabetic Supplies in Support of "Mr. Diabetes(R)" and the Defeat Diabetes Foundation
- MannKind Reports Positive Data From a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
- CORRECTING and REPLACING New Clinical Trial Demonstrates Diachrome(R) Safely Lowers Blood Sugar Levels in People With Type 2 Diabetes; Results of Long-Term Study Evaluating Diachrome Presented at American Diabetes Association 66th Annual...
- MannKind Corporation Announces Positive Results From a Phase 2b Dose-Ranging Study of Technosphere(R) Insulin in Patients With Type 2 Diabetes
- Phase 2 Study Shows Lilly/Alkermes Inhaled Insulin System Achieved Blood Sugar Levels Similar to Injected Insulin; 80 Percent of Diabetes Patients in Study Preferred Inhaled Insulin System to Mealtime Injections
- Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes: The Diabetes Prevention Trial-Type 1
- Variation in NCB5OR: Studies of Relationships to Type 2 Diabetes, Maturity-Onset Diabetes of the Young, and Gestational Diabetes Mellitus
- Case Study: Diabetic Ketoacidosis in Type 2 Diabetes: "Look Under the Sheets"
- Comparing the Long-Term Cost-Effectiveness of Repaglinide Plus Metformin Versus Nateglinide Plus Metformin in Type 2 Diabetes Patients With Inadequate Glycaemic Control: An Application of the CORE Diabetes Model in Type 2 Diabetes
User Comments (0)

RSS Feeds